In the closing discussion, the panel looks ahead to how IgA nephropathy treatment may continue to evolve. They highlight growing momentum toward earlier, mechanism-based intervention, particularly with B-cell pathway modulators that reduce production of galactose-deficient IgA1 at its origin. The group emphasizes the need for long-term data to understand durability of proteinuria response, immunoglobulin stability, and overall kidney function trajectories with extended use of these therapies. They also discuss the future role of biomarkers—including serum Gd-IgA1 levels, complement activation markers, and genetic signatures—which may eventually help match the right therapy to the right patient rather than relying primarily on proteinuria thresholds. Combination strategies are noted as an emerging research priority, especially pairing supportive care with targeted immunomodulation. The panel closes by expressing optimism that continued collaboration among clinicians, researchers, and patients will meaningfully improve outcomes and reduce progression to kidney failure over time.